We've found
7,711
archived clinical trials in
Depression
We've found
7,711
archived clinical trials in
Depression
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
AZD6765 Severe Major Depressive Disorder (MDD) IV
Updated: 7/16/2012
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Updated: 7/18/2012
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Pilot Trial of CenteringPregnancy With Mindfulness Skills
Updated: 7/18/2012
Integrative Stress Reduction for Maternal-Child Health
Status: Enrolling
Updated: 7/18/2012
Pilot Trial of CenteringPregnancy With Mindfulness Skills
Updated: 7/18/2012
Integrative Stress Reduction for Maternal-Child Health
Status: Enrolling
Updated: 7/18/2012
Click here to add this to my saved trials

Yoga for Stress and Mental Health
Updated: 7/25/2012
An 8-Week Hatha Yoga Intervention for Stress and Mental Health
Status: Enrolling
Updated: 7/25/2012
Yoga for Stress and Mental Health
Updated: 7/25/2012
An 8-Week Hatha Yoga Intervention for Stress and Mental Health
Status: Enrolling
Updated: 7/25/2012
Click here to add this to my saved trials

Antidepressant Therapy in Treating Bipolar Type II Major Depression
Updated: 7/26/2012
Treatment of Bipolar Type II Major Depression
Status: Enrolling
Updated: 7/26/2012
Antidepressant Therapy in Treating Bipolar Type II Major Depression
Updated: 7/26/2012
Treatment of Bipolar Type II Major Depression
Status: Enrolling
Updated: 7/26/2012
Click here to add this to my saved trials

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
Updated: 7/27/2012
A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs.
Status: Enrolling
Updated: 7/27/2012
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
Updated: 7/27/2012
A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs.
Status: Enrolling
Updated: 7/27/2012
Click here to add this to my saved trials

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
Updated: 7/27/2012
A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs.
Status: Enrolling
Updated: 7/27/2012
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
Updated: 7/27/2012
A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs.
Status: Enrolling
Updated: 7/27/2012
Click here to add this to my saved trials

Prevention of Relapse & Recurrence of Bipolar Depression
Updated: 7/27/2012
Prevention of Relapse & Recurrence of Bipolar Depression
Status: Enrolling
Updated: 7/27/2012
Prevention of Relapse & Recurrence of Bipolar Depression
Updated: 7/27/2012
Prevention of Relapse & Recurrence of Bipolar Depression
Status: Enrolling
Updated: 7/27/2012
Click here to add this to my saved trials

Prevention of Relapse & Recurrence of Bipolar Depression
Updated: 7/27/2012
Prevention of Relapse & Recurrence of Bipolar Depression
Status: Enrolling
Updated: 7/27/2012
Prevention of Relapse & Recurrence of Bipolar Depression
Updated: 7/27/2012
Prevention of Relapse & Recurrence of Bipolar Depression
Status: Enrolling
Updated: 7/27/2012
Click here to add this to my saved trials

Integrated Treatment for Comorbid Depression and Obesity in Adolescents
Updated: 7/28/2012
Integrated Treatment for Comorbid Depression and Obesity in Adolescents
Status: Enrolling
Updated: 7/28/2012
Integrated Treatment for Comorbid Depression and Obesity in Adolescents
Updated: 7/28/2012
Integrated Treatment for Comorbid Depression and Obesity in Adolescents
Status: Enrolling
Updated: 7/28/2012
Click here to add this to my saved trials

Quetiapine in Melancholic Depression
Updated: 7/31/2012
Quetiapine in Melancholic Depression: an fMRI Study of Treatment-induced Changes in the Neurocircuitry of the Stress Response
Status: Enrolling
Updated: 7/31/2012
Quetiapine in Melancholic Depression
Updated: 7/31/2012
Quetiapine in Melancholic Depression: an fMRI Study of Treatment-induced Changes in the Neurocircuitry of the Stress Response
Status: Enrolling
Updated: 7/31/2012
Click here to add this to my saved trials

Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
Updated: 8/20/2012
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
Updated: 8/20/2012
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Click here to add this to my saved trials

Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
Updated: 8/20/2012
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
Updated: 8/20/2012
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Click here to add this to my saved trials
